It Is Time to Determine Tocilizumab's Place in Coronavirus Disease 2019 (COVID-19).

Timothée, Klopfenstein; Gerazime, Aurélie; Puyraveau, Marc; Kadiane-Oussou, N'dri Juliette; Gendrin, Vincent; Zayet, Souheil

Timothée, Klopfenstein; Gerazime, Aurélie; Puyraveau, Marc; Kadiane-Oussou, N'dri Juliette; Gendrin, Vincent; Zayet, Souheil.

Afiliación

Timothée K; Infectious Disease Department, Nord Franche-Comté Hospital, Trevenans, France.
Gerazime A; Methodology Unit, Clinical Investigation Center, INSERM 1431, Jean-Minjoz University Hospital, Besançon, France.
Puyraveau M; Methodology Unit, Clinical Investigation Center, INSERM 1431, Jean-Minjoz University Hospital, Besançon, France.
Kadiane-Oussou NJ; Infectious Disease Department, Nord Franche-Comté Hospital, Trevenans, France.
Gendrin V; Infectious Disease Department, Nord Franche-Comté Hospital, Trevenans, France.
Zayet S; Infectious Disease Department, Nord Franche-Comté Hospital, Trevenans, France.

Clin Infect Dis ; 74(3): 560-562, 2022 02 11.

Article en En | MEDLINE | ID: mdl-34036334

Asunto(s)

Tratamiento Farmacológico de COVID-19; Anticuerpos Monoclonales Humanizados; Humanos; SARS-CoV-2

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tratamiento Farmacológico de COVID-19 Límite: Humans Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2022 Tipo del documento: Article País de afiliación: Francia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google